Xenon Pharmaceuticals temporarily pauses new patient enrollment in studies
Xenon Pharmaceuticals (XENE) said it has temporarily paused enrolling new patients in clinical studies for its experimental treatment for major depression and bipolar disorder due to reports of mental and nervous-system-related side effects.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.